Yuen Steffi Kar Kei, Castellani Daniele, Tokas Theodoros, Pirola Giacomo Maria, Giulioni Carlo, Kwok Jia-Lun, Lakmichi Mohamed Amine, Yanagisawa Takafumi, Pietropaolo Amelia, Herrmann Thomas, Somani Bhaskar, Gauhar Vineet
SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
European Association of Urology Section of Endourology, Arnhem, The Netherlands.
World J Urol. 2025 Aug 12;43(1):489. doi: 10.1007/s00345-025-05848-2.
Ureteroscopy serves as a minimally invasive surgical treatment option for ureteral and kidney stones but is not without technical challenges. Pre-stenting and medical therapies, such as alpha-blockers, may improve outcomes by facilitating ureteral access sheath placements and reducing complications. This systematic review and meta-analysis aimed to evaluate the effects of pre-stenting and preoperative pharmacological agents on ureteroscopy outcomes.
We conducted a systematic review and meta-analysis following PRISMA guidelines. A comprehensive literature search was performed across multiple databases, identifying randomized controlled trials comparing ureteroscopy outcomes with and without pre-stenting and pre-ureteroscopy medical therapy. Primary outcomes included failure rates in accessing the upper urinary tract, while secondary outcomes encompassed operative times, complications, and stone-free rates.
The analysis included 16 randomized controlled trials, revealing that pre-stenting and medical therapy significantly reduced failure rates (Relative Ratio 0.44, 95% CI 0.33-0.59, p < 0.001) and operative times (Mean Difference -10.81 min, 95% CI -13.45 to -8.18, p < 0.001). Additionally, there was a higher stone-free rates, lower need for postoperative stenting and fewer complications associated with preoperative ureteral dilation interventions.
Preoperative alpha blockers enhance ureteroscopy success and reduces complications. The evidence supports their use before ureteroscopy for renal and ureteral stones, improving patient outcomes and procedural efficiency. Patients pre-stented for any reason demonstrated significantly improved ureteroscopic access and stone-free rates.
输尿管镜检查是输尿管和肾结石的一种微创手术治疗选择,但并非没有技术挑战。预先置入支架和药物治疗,如α受体阻滞剂,可能通过促进输尿管通路鞘的放置和减少并发症来改善治疗效果。本系统评价和荟萃分析旨在评估预先置入支架和术前药物治疗对输尿管镜检查结果的影响。
我们按照PRISMA指南进行了系统评价和荟萃分析。在多个数据库中进行了全面的文献检索,确定了比较有或没有预先置入支架及输尿管镜术前药物治疗的输尿管镜检查结果的随机对照试验。主要结局包括上尿路进入失败率,次要结局包括手术时间、并发症和结石清除率。
分析纳入了16项随机对照试验,结果显示预先置入支架和药物治疗显著降低了失败率(相对比0.44,95%可信区间0.33-0.59,p<0.001)和手术时间(平均差-10.81分钟,95%可信区间-13.45至-8.18,p<0.001)。此外,结石清除率更高,术后支架置入需求更低,且与术前输尿管扩张干预相关的并发症更少。
术前使用α受体阻滞剂可提高输尿管镜检查的成功率并减少并发症。证据支持在输尿管镜检查前用于治疗肾和输尿管结石,可改善患者治疗效果和手术效率。因任何原因预先置入支架的患者输尿管镜检查通路和结石清除率均显著提高。